Clinical trial NCT02054442 (phase 1/phase 2, status: active, not recruiting)
Conditions: squamous cell carcinoma of the head and neck
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: cetuximab, methotrexate
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Cytologically/histologically-proven SCCHN

          -  Recurrent or metastatic SCCHN

          -  At least one measurable lesion as determined by RECIST v1.1 is required. Lesions in
             previously irradiated areas should not be considered measurable unless there is clear
             evidence of progression in such lesions since the radiotherapy.

          -  No prior systemic treatment for recurrent or metastatic disease

          -  Primary site: (1) oral cavity, (2) oropharynx, (3) hypopharynx, (4) larynx, or (5)
             unknown primary squamous cell carcinoma in the head and neck region presenting
             originally with lymph node metastases (N1-N3).

          -  Time between prior treatment and inclusion in the study (> 3 months). Palliative RT in
             case of painful bone metastases is allowed in phase II and after 4 weeks in phase Ib

          -  Ineligible (due to medical co-morbidities) or intolerant to platinum-based therapy per
             medical history or refusing cisplatin-based chemotherapy by the patient

          -  WHO performance status 0-2.

          -  Age >18 years

          -  Adequate organ function and laboratory parameters as defined by:

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109 /L

               -  Hemoglobin (Hb) ≥ 9 g/dl 5.6 mmol/l (which may be achieved by transfusion)

               -  Platelets (PLT) ≥ 100 x 109/L

               -  AST and ALT ≤ 2.5 x ULN (upper limit of normal)

               -  Serum bilirubin ≤ 1.5 x ULN

               -  Calculated creatinine clearance or MDRD > 60ml/min

          -  Recovered from all adverse events (AEs) of previous anti-cancer therapies. AEs related
             to prior radiotherapy are allowed.

          -  Written informed consent

        Exclusion Criteria:

          -  Serious active infections

          -  Patients (M/F) with reproductive potential not implementing adequate contraceptives
             measures

          -  Prior treatment with EGFR inhibitors or MTX

          -  Concomitant (or within 4 weeks before randomization) administration of any other
             experimental drug under investigation

          -  Concurrent treatment with any other anti-cancer therapy.

          -  Central nervous system involvement

          -  Lung fibrosis

          -  Pleural effusion or ascites or other third space effusions

          -  History of another malignancy within 2 years prior to starting study treatment, except
             cured basal cell carcinoma of the skin, excised carcinoma in situ of the cervix, or
             other head and neck cancer.

          -  Pregnancy or lactation

          -  Any other condition that would, in the Investigator's judgment, preclude patient's
             participation in the clinical study due to safety concerns or compliance with clinical
             study procedures, e.g. infection/inflammation, intestinal obstruction,
             social/psychological complications.